Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study
Despite intensive insulin treatment, many patients with type-1 diabetes (T1DM) have longstanding inadequate glycaemic control. Metformin is an oral hypoglycaemic agent that improves insulin action in patients with type-2 diabetes. We investigated the effect of a one-year treatment with metformin ver...
Gespeichert in:
| Veröffentlicht in: | PloS one 2008-10, Vol.3 (10), p.e3363-e3363 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e3363 |
|---|---|
| container_issue | 10 |
| container_start_page | e3363 |
| container_title | PloS one |
| container_volume | 3 |
| creator | Lund, Søren Søgaard Tarnow, Lise Astrup, Anne Sofie Hovind, Peter Jacobsen, Peter Karl Alibegovic, Amra Ciric Parving, Ida Pietraszek, Lotte Frandsen, Merete Rossing, Peter Parving, Hans-Henrik Vaag, Allan Arthur |
| description | Despite intensive insulin treatment, many patients with type-1 diabetes (T1DM) have longstanding inadequate glycaemic control. Metformin is an oral hypoglycaemic agent that improves insulin action in patients with type-2 diabetes. We investigated the effect of a one-year treatment with metformin versus placebo in patients with T1DM and persistent poor glycaemic control.
One hundred patients with T1DM, preserved hypoglycaemic awareness and HaemoglobinA(1c) (HbA(1c)) > or = 8.5% during the year before enrolment entered a one-month run-in on placebo treatment. Thereafter, patients were randomized (baseline) to treatment with either metformin (1 g twice daily) or placebo for 12 months (double-masked). Patients continued ongoing insulin therapy and their usual outpatient clinical care. The primary outcome measure was change in HbA(1c) after one year of treatment. At enrolment, mean (standard deviation) HbA(1c) was 9.48% (0.99) for the metformin group (n = 49) and 9.60% (0.86) for the placebo group (n = 51). Mean (95% confidence interval) baseline-adjusted differences after 12 months with metformin (n = 48) versus placebo (n = 50) were: HbA(1c), 0.13% (-0.19; 0.44), p = 0.422; Total daily insulin dose, -5.7 U/day (-8.6; -2.9), p |
| doi_str_mv | 10.1371/journal.pone.0003363 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1312439170</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A472612201</galeid><doaj_id>oai_doaj_org_article_3dcf5adfad684ed5a0fd2f09f2ddfa78</doaj_id><sourcerecordid>A472612201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c662t-decfc774fd094dd92faab2bbf8ef1aff4d25eca60344b3f5e371de3ccb3fbdce3</originalsourceid><addsrcrecordid>eNqNk19rFDEQwBdRbK1-A9GAUPDhzvzZze6-FEqpWigU_PcaZpPJXY7dzTXJqucH8HOb807tiQ-Sh0wmv5nJzGSK4imjcyZq9mrlpzBCP1_7EeeUUiGkuFccs1bwmeRU3L8jHxWPYlxRWolGyofFEWuaijd1dVx8v7QWdSLeEjCraczigMn6MLiRpICQBhwTyYc1JJfFSL64tCRps8YZI8ZBhwkjgdGQNYboYtrxYPB2goRk0W804OA00X5Mwfdzck5C5v3gvqEhMU1m87h4YKGP-GS_nxQfX19-uHg7u755c3Vxfj3TUvI0M6itruvSGtqWxrTcAnS862yDloG1peEVapBUlGUnbIW5UAaF1vnQGY3ipHi-87vufVT7EkbFBOOlaFlNM3G1I4yHlVoHN0DYKA9O_VT4sFAQktM9KmG0rcBYMLIp0VRAreGWtpabrKyb7OtsH23qBszxc_7QHzg9vBndUi38Z8UrKWXu1klxuncQ_O2EManBRY19DyP6KSrZyqpthcjgi7_Af-c231ELyM93o_U5qs7LbPuT_5F1WX9e1lwyzinLBi8PDLYdxK9pAVOM6ur9u_9nbz4dsqd32CVCn5bR91NyfoyHYLkDdfAxBrS_i8eo2o7BrzzVdgzUfgyy2bO7hf9jtP_34gdxngli</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1312439170</pqid></control><display><type>article</type><title>Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Lund, Søren Søgaard ; Tarnow, Lise ; Astrup, Anne Sofie ; Hovind, Peter ; Jacobsen, Peter Karl ; Alibegovic, Amra Ciric ; Parving, Ida ; Pietraszek, Lotte ; Frandsen, Merete ; Rossing, Peter ; Parving, Hans-Henrik ; Vaag, Allan Arthur</creator><creatorcontrib>Lund, Søren Søgaard ; Tarnow, Lise ; Astrup, Anne Sofie ; Hovind, Peter ; Jacobsen, Peter Karl ; Alibegovic, Amra Ciric ; Parving, Ida ; Pietraszek, Lotte ; Frandsen, Merete ; Rossing, Peter ; Parving, Hans-Henrik ; Vaag, Allan Arthur</creatorcontrib><description>Despite intensive insulin treatment, many patients with type-1 diabetes (T1DM) have longstanding inadequate glycaemic control. Metformin is an oral hypoglycaemic agent that improves insulin action in patients with type-2 diabetes. We investigated the effect of a one-year treatment with metformin versus placebo in patients with T1DM and persistent poor glycaemic control.
One hundred patients with T1DM, preserved hypoglycaemic awareness and HaemoglobinA(1c) (HbA(1c)) > or = 8.5% during the year before enrolment entered a one-month run-in on placebo treatment. Thereafter, patients were randomized (baseline) to treatment with either metformin (1 g twice daily) or placebo for 12 months (double-masked). Patients continued ongoing insulin therapy and their usual outpatient clinical care. The primary outcome measure was change in HbA(1c) after one year of treatment. At enrolment, mean (standard deviation) HbA(1c) was 9.48% (0.99) for the metformin group (n = 49) and 9.60% (0.86) for the placebo group (n = 51). Mean (95% confidence interval) baseline-adjusted differences after 12 months with metformin (n = 48) versus placebo (n = 50) were: HbA(1c), 0.13% (-0.19; 0.44), p = 0.422; Total daily insulin dose, -5.7 U/day (-8.6; -2.9), p<0.001; body weight, -1.74 kg (-3.32; -0.17), p = 0.030. Minor and overall major hypoglycaemia was not significantly different between treatments. Treatments were well tolerated.
In patients with poorly controlled T1DM, adjunct metformin therapy did not provide any improvement of glycaemic control after one year. Nevertheless, adjunct metformin treatment was associated with sustained reductions of insulin dose and body weight. Further investigations into the potential cardiovascular-protective effects of metformin therapy in patients with T1DM are warranted.
ClinicalTrials.gov NCT00118937.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0003363</identifier><identifier>PMID: 18852875</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Antidiabetics ; Blood Glucose - drug effects ; Body composition ; Body weight ; Body Weight - drug effects ; Cardiovascular disease ; Care and treatment ; Classification ; Confidence intervals ; Diabetes ; Diabetes and Endocrinology ; Diabetes and Endocrinology/Obesity ; Diabetes and Endocrinology/Type 1 Diabetes ; Diabetes mellitus ; Diabetes Mellitus, Type 1 - drug therapy ; Diabetes therapy ; Drug dosages ; Endocrinology ; Female ; Glucose ; Glycated Hemoglobin A - analysis ; Heart attacks ; Hemoglobin ; Humans ; Hyperglycemia ; Hypoglycemia ; Hypoglycemic Agents - therapeutic use ; Insulin ; Insulin - administration & dosage ; Insulin - therapeutic use ; Insulin resistance ; Male ; Medical research ; Medicine ; Metabolism ; Metformin ; Metformin - administration & dosage ; Middle Aged ; Mortality ; Obesity ; Patients ; Randomization ; Studies ; Therapy ; Treatment Outcome ; Type 1 diabetes ; Type 2 diabetes ; Weight reduction</subject><ispartof>PloS one, 2008-10, Vol.3 (10), p.e3363-e3363</ispartof><rights>COPYRIGHT 2008 Public Library of Science</rights><rights>2008 Lund et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Lund et al. 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c662t-decfc774fd094dd92faab2bbf8ef1aff4d25eca60344b3f5e371de3ccb3fbdce3</citedby><cites>FETCH-LOGICAL-c662t-decfc774fd094dd92faab2bbf8ef1aff4d25eca60344b3f5e371de3ccb3fbdce3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566605/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566605/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79342,79343</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18852875$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lund, Søren Søgaard</creatorcontrib><creatorcontrib>Tarnow, Lise</creatorcontrib><creatorcontrib>Astrup, Anne Sofie</creatorcontrib><creatorcontrib>Hovind, Peter</creatorcontrib><creatorcontrib>Jacobsen, Peter Karl</creatorcontrib><creatorcontrib>Alibegovic, Amra Ciric</creatorcontrib><creatorcontrib>Parving, Ida</creatorcontrib><creatorcontrib>Pietraszek, Lotte</creatorcontrib><creatorcontrib>Frandsen, Merete</creatorcontrib><creatorcontrib>Rossing, Peter</creatorcontrib><creatorcontrib>Parving, Hans-Henrik</creatorcontrib><creatorcontrib>Vaag, Allan Arthur</creatorcontrib><title>Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Despite intensive insulin treatment, many patients with type-1 diabetes (T1DM) have longstanding inadequate glycaemic control. Metformin is an oral hypoglycaemic agent that improves insulin action in patients with type-2 diabetes. We investigated the effect of a one-year treatment with metformin versus placebo in patients with T1DM and persistent poor glycaemic control.
One hundred patients with T1DM, preserved hypoglycaemic awareness and HaemoglobinA(1c) (HbA(1c)) > or = 8.5% during the year before enrolment entered a one-month run-in on placebo treatment. Thereafter, patients were randomized (baseline) to treatment with either metformin (1 g twice daily) or placebo for 12 months (double-masked). Patients continued ongoing insulin therapy and their usual outpatient clinical care. The primary outcome measure was change in HbA(1c) after one year of treatment. At enrolment, mean (standard deviation) HbA(1c) was 9.48% (0.99) for the metformin group (n = 49) and 9.60% (0.86) for the placebo group (n = 51). Mean (95% confidence interval) baseline-adjusted differences after 12 months with metformin (n = 48) versus placebo (n = 50) were: HbA(1c), 0.13% (-0.19; 0.44), p = 0.422; Total daily insulin dose, -5.7 U/day (-8.6; -2.9), p<0.001; body weight, -1.74 kg (-3.32; -0.17), p = 0.030. Minor and overall major hypoglycaemia was not significantly different between treatments. Treatments were well tolerated.
In patients with poorly controlled T1DM, adjunct metformin therapy did not provide any improvement of glycaemic control after one year. Nevertheless, adjunct metformin treatment was associated with sustained reductions of insulin dose and body weight. Further investigations into the potential cardiovascular-protective effects of metformin therapy in patients with T1DM are warranted.
ClinicalTrials.gov NCT00118937.</description><subject>Adult</subject><subject>Antidiabetics</subject><subject>Blood Glucose - drug effects</subject><subject>Body composition</subject><subject>Body weight</subject><subject>Body Weight - drug effects</subject><subject>Cardiovascular disease</subject><subject>Care and treatment</subject><subject>Classification</subject><subject>Confidence intervals</subject><subject>Diabetes</subject><subject>Diabetes and Endocrinology</subject><subject>Diabetes and Endocrinology/Obesity</subject><subject>Diabetes and Endocrinology/Type 1 Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Diabetes therapy</subject><subject>Drug dosages</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Glucose</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>Heart attacks</subject><subject>Hemoglobin</subject><subject>Humans</subject><subject>Hyperglycemia</subject><subject>Hypoglycemia</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin</subject><subject>Insulin - administration & dosage</subject><subject>Insulin - therapeutic use</subject><subject>Insulin resistance</subject><subject>Male</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Metabolism</subject><subject>Metformin</subject><subject>Metformin - administration & dosage</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Obesity</subject><subject>Patients</subject><subject>Randomization</subject><subject>Studies</subject><subject>Therapy</subject><subject>Treatment Outcome</subject><subject>Type 1 diabetes</subject><subject>Type 2 diabetes</subject><subject>Weight reduction</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk19rFDEQwBdRbK1-A9GAUPDhzvzZze6-FEqpWigU_PcaZpPJXY7dzTXJqucH8HOb807tiQ-Sh0wmv5nJzGSK4imjcyZq9mrlpzBCP1_7EeeUUiGkuFccs1bwmeRU3L8jHxWPYlxRWolGyofFEWuaijd1dVx8v7QWdSLeEjCraczigMn6MLiRpICQBhwTyYc1JJfFSL64tCRps8YZI8ZBhwkjgdGQNYboYtrxYPB2goRk0W804OA00X5Mwfdzck5C5v3gvqEhMU1m87h4YKGP-GS_nxQfX19-uHg7u755c3Vxfj3TUvI0M6itruvSGtqWxrTcAnS862yDloG1peEVapBUlGUnbIW5UAaF1vnQGY3ipHi-87vufVT7EkbFBOOlaFlNM3G1I4yHlVoHN0DYKA9O_VT4sFAQktM9KmG0rcBYMLIp0VRAreGWtpabrKyb7OtsH23qBszxc_7QHzg9vBndUi38Z8UrKWXu1klxuncQ_O2EManBRY19DyP6KSrZyqpthcjgi7_Af-c231ELyM93o_U5qs7LbPuT_5F1WX9e1lwyzinLBi8PDLYdxK9pAVOM6ur9u_9nbz4dsqd32CVCn5bR91NyfoyHYLkDdfAxBrS_i8eo2o7BrzzVdgzUfgyy2bO7hf9jtP_34gdxngli</recordid><startdate>20081009</startdate><enddate>20081009</enddate><creator>Lund, Søren Søgaard</creator><creator>Tarnow, Lise</creator><creator>Astrup, Anne Sofie</creator><creator>Hovind, Peter</creator><creator>Jacobsen, Peter Karl</creator><creator>Alibegovic, Amra Ciric</creator><creator>Parving, Ida</creator><creator>Pietraszek, Lotte</creator><creator>Frandsen, Merete</creator><creator>Rossing, Peter</creator><creator>Parving, Hans-Henrik</creator><creator>Vaag, Allan Arthur</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20081009</creationdate><title>Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study</title><author>Lund, Søren Søgaard ; Tarnow, Lise ; Astrup, Anne Sofie ; Hovind, Peter ; Jacobsen, Peter Karl ; Alibegovic, Amra Ciric ; Parving, Ida ; Pietraszek, Lotte ; Frandsen, Merete ; Rossing, Peter ; Parving, Hans-Henrik ; Vaag, Allan Arthur</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c662t-decfc774fd094dd92faab2bbf8ef1aff4d25eca60344b3f5e371de3ccb3fbdce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Antidiabetics</topic><topic>Blood Glucose - drug effects</topic><topic>Body composition</topic><topic>Body weight</topic><topic>Body Weight - drug effects</topic><topic>Cardiovascular disease</topic><topic>Care and treatment</topic><topic>Classification</topic><topic>Confidence intervals</topic><topic>Diabetes</topic><topic>Diabetes and Endocrinology</topic><topic>Diabetes and Endocrinology/Obesity</topic><topic>Diabetes and Endocrinology/Type 1 Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Diabetes therapy</topic><topic>Drug dosages</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Glucose</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>Heart attacks</topic><topic>Hemoglobin</topic><topic>Humans</topic><topic>Hyperglycemia</topic><topic>Hypoglycemia</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin</topic><topic>Insulin - administration & dosage</topic><topic>Insulin - therapeutic use</topic><topic>Insulin resistance</topic><topic>Male</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Metabolism</topic><topic>Metformin</topic><topic>Metformin - administration & dosage</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Obesity</topic><topic>Patients</topic><topic>Randomization</topic><topic>Studies</topic><topic>Therapy</topic><topic>Treatment Outcome</topic><topic>Type 1 diabetes</topic><topic>Type 2 diabetes</topic><topic>Weight reduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lund, Søren Søgaard</creatorcontrib><creatorcontrib>Tarnow, Lise</creatorcontrib><creatorcontrib>Astrup, Anne Sofie</creatorcontrib><creatorcontrib>Hovind, Peter</creatorcontrib><creatorcontrib>Jacobsen, Peter Karl</creatorcontrib><creatorcontrib>Alibegovic, Amra Ciric</creatorcontrib><creatorcontrib>Parving, Ida</creatorcontrib><creatorcontrib>Pietraszek, Lotte</creatorcontrib><creatorcontrib>Frandsen, Merete</creatorcontrib><creatorcontrib>Rossing, Peter</creatorcontrib><creatorcontrib>Parving, Hans-Henrik</creatorcontrib><creatorcontrib>Vaag, Allan Arthur</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection (ProQuest)</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lund, Søren Søgaard</au><au>Tarnow, Lise</au><au>Astrup, Anne Sofie</au><au>Hovind, Peter</au><au>Jacobsen, Peter Karl</au><au>Alibegovic, Amra Ciric</au><au>Parving, Ida</au><au>Pietraszek, Lotte</au><au>Frandsen, Merete</au><au>Rossing, Peter</au><au>Parving, Hans-Henrik</au><au>Vaag, Allan Arthur</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2008-10-09</date><risdate>2008</risdate><volume>3</volume><issue>10</issue><spage>e3363</spage><epage>e3363</epage><pages>e3363-e3363</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Despite intensive insulin treatment, many patients with type-1 diabetes (T1DM) have longstanding inadequate glycaemic control. Metformin is an oral hypoglycaemic agent that improves insulin action in patients with type-2 diabetes. We investigated the effect of a one-year treatment with metformin versus placebo in patients with T1DM and persistent poor glycaemic control.
One hundred patients with T1DM, preserved hypoglycaemic awareness and HaemoglobinA(1c) (HbA(1c)) > or = 8.5% during the year before enrolment entered a one-month run-in on placebo treatment. Thereafter, patients were randomized (baseline) to treatment with either metformin (1 g twice daily) or placebo for 12 months (double-masked). Patients continued ongoing insulin therapy and their usual outpatient clinical care. The primary outcome measure was change in HbA(1c) after one year of treatment. At enrolment, mean (standard deviation) HbA(1c) was 9.48% (0.99) for the metformin group (n = 49) and 9.60% (0.86) for the placebo group (n = 51). Mean (95% confidence interval) baseline-adjusted differences after 12 months with metformin (n = 48) versus placebo (n = 50) were: HbA(1c), 0.13% (-0.19; 0.44), p = 0.422; Total daily insulin dose, -5.7 U/day (-8.6; -2.9), p<0.001; body weight, -1.74 kg (-3.32; -0.17), p = 0.030. Minor and overall major hypoglycaemia was not significantly different between treatments. Treatments were well tolerated.
In patients with poorly controlled T1DM, adjunct metformin therapy did not provide any improvement of glycaemic control after one year. Nevertheless, adjunct metformin treatment was associated with sustained reductions of insulin dose and body weight. Further investigations into the potential cardiovascular-protective effects of metformin therapy in patients with T1DM are warranted.
ClinicalTrials.gov NCT00118937.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>18852875</pmid><doi>10.1371/journal.pone.0003363</doi><tpages>e3363</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2008-10, Vol.3 (10), p.e3363-e3363 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1312439170 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Adult Antidiabetics Blood Glucose - drug effects Body composition Body weight Body Weight - drug effects Cardiovascular disease Care and treatment Classification Confidence intervals Diabetes Diabetes and Endocrinology Diabetes and Endocrinology/Obesity Diabetes and Endocrinology/Type 1 Diabetes Diabetes mellitus Diabetes Mellitus, Type 1 - drug therapy Diabetes therapy Drug dosages Endocrinology Female Glucose Glycated Hemoglobin A - analysis Heart attacks Hemoglobin Humans Hyperglycemia Hypoglycemia Hypoglycemic Agents - therapeutic use Insulin Insulin - administration & dosage Insulin - therapeutic use Insulin resistance Male Medical research Medicine Metabolism Metformin Metformin - administration & dosage Middle Aged Mortality Obesity Patients Randomization Studies Therapy Treatment Outcome Type 1 diabetes Type 2 diabetes Weight reduction |
| title | Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T15%3A51%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20adjunct%20metformin%20treatment%20in%20patients%20with%20type-1%20diabetes%20and%20persistent%20inadequate%20glycaemic%20control.%20A%20randomized%20study&rft.jtitle=PloS%20one&rft.au=Lund,%20S%C3%B8ren%20S%C3%B8gaard&rft.date=2008-10-09&rft.volume=3&rft.issue=10&rft.spage=e3363&rft.epage=e3363&rft.pages=e3363-e3363&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0003363&rft_dat=%3Cgale_plos_%3EA472612201%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1312439170&rft_id=info:pmid/18852875&rft_galeid=A472612201&rft_doaj_id=oai_doaj_org_article_3dcf5adfad684ed5a0fd2f09f2ddfa78&rfr_iscdi=true |